Fol. Biol. 2013, 59, 87-92
https://doi.org/10.14712/fb2013059020087
Promoter Methylation of GATA4, WIF1, NTRK1 and Other Selected Tumour Suppressor Genes in Ovarian Cancer
References
1. 2011) Methylation status of the gene promoter of cyclin-dependent kinase inhibitor 2A (CDKN2A) in ovarian cancer. Scand. J. Clin. Lab. Invest. 71, 542-547.
< , A. A., Azzam, A. Z., Kamel, N. A. (https://doi.org/10.3109/00365513.2011.590224>
2. 2010) Epigenetics of ovarian cancer: from the lab to the clinic. Gynecol. Oncol. 118, 81-87.
< , R., Hyde, C. A., Zhong, X. Y. (https://doi.org/10.1016/j.ygyno.2010.03.015>
3. 2010) Methylation profiles of hereditary and sporadic ovarian cancer. Histopathology 57, 363-370.
< , G. M., Suijkerbuijk, K. P., Bart, J., Vooijs, M., van der Wall, E., van Diest, P. J. (https://doi.org/10.1111/j.1365-2559.2010.03642.x>
4. 2002) Epigenetic factors controlling the BRCA1 and BRCA2 genes in sporadic ovarian cancer. Cancer Res. 62, 4151-4156.
, K. Y., Ozçelik, H., Cheung, A. N., Ngan, H. Y., Khoo, U. S. (
5. 2013) Methylation in the p53 promoter in epithelial ovarian cancer. Clin. Transl. Oncol. 15, 160-163.
< , M., Krepinska, E., Spacek, J., Laco, J., Beranek, M., Palicka, V. (https://doi.org/10.1007/s12094-012-0894-z>
6. 2010) Epigenetic silencing of WIF-1 in hepatocellular carcinomas. J. Cancer Res. Clin. Oncol. 136, 1161-1167.
< , Y., Yu, B., Cheng, Q., Jin, J., You, H., Ke, R., Tang, N., Shen, Q., Shu, H., Yao, G., Zhang, Z., Qin, W. (https://doi.org/10.1007/s00432-010-0763-5>
7. 2012) Frequent SLIT2 promoter methylation in the serum of patients with ovarian cancer. J. Int. Med. Res. 40, 681-686.
< , R., Yu, J., Pu, H., Zhang, Z., Xu, X. (https://doi.org/10.1177/147323001204000231>
8. 2008) Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation. Cancer 112, 1489-1502.
< , W., Marquez, R. T., Lu, Z., Liu, J., Lu, K. H., Issa, J. P., Fishman, D. M., Yu, Y., Bast, R. C. Jr. (https://doi.org/10.1002/cncr.23323>
9. 2001) Microsatellite instability, MLH-1 promoter hypermethylation, and frameshift mutations at coding mononucleotide repeat microsatellites in ovarian tumors. Cancer 92, 2829-2836.
< , E., Catasus, L., Argüelles, R., Moreno-Bueno, G., Palacios, J., Gamallo, C., Matias-Guiu, X., Prat, J. (https://doi.org/10.1002/1097-0142(20011201)92:11<2829::AID-CNCR10094>3.0.CO;2-3>
10. 2004) Hypermethylation of the GATA genes in lung cancer. Clin. Cancer Res. 10, 7917-7924.
< , M., Akiyama, Y., House, M. G., Hooker, C. M., Heath, E., Gabrielson, E., Yang, S. C., Han, Y., Baylin, S. B., Herman, J. G., Brock, M. V. (https://doi.org/10.1158/1078-0432.CCR-04-1140>
11. 2006) Hypermethylation of the GATA gene family in esophageal cancer. Int. J. Cancer 119, 2078-2083.
< , M., House, M. G., Akiyama, Y., Qi, Y., Capagna, D., Harmon, J., Baylin, S. B., Brock, M. V., Herman, J. G. (https://doi.org/10.1002/ijc.22092>
12. 2009) GATA4 and GATA5 are potential tumor suppressors and biomarkers in colorectal cancer. Clin. Cancer Res. 15, 3990-3997.
< , D. M., Lentjes, M. H., van den Bosch, S. M., Melotte, V., Wouters, K. A., Daenen, K. L., Smits, K. M., Akiyama, Y., Yuasa, Y., Sanduleanu, S., Khalid-de Bakker, C. A., Jonkers, D., Weijenberg, M. P., Louwagie, J., van Criekinge, W., Carvalho, B., Meijer, G. A., Baylin, S. B., Herman, J. G., de Bruïne, A. P., van Engeland, M. (https://doi.org/10.1158/1078-0432.CCR-09-0055>
13. 2004) Tumour cell-specific BRCA1 and RASSF1A hypermethylation in serum, plasma, and peritoneal fluid from ovarian cancer patients. Cancer Res. 64, 6476-6481.
< , I., Battagli, C., Esteller, M., Herman, J. G., Dulaimi, E., Edelson, M. I., Bergman, C., Ehya, H., Eisenberg, B. L., Cairns, P. (https://doi.org/10.1158/0008-5472.CAN-04-1529>
14. 2007) The epigenomics of cancer. Cell 128, 683-692.
< , P. A., Baylin, S. B. (https://doi.org/10.1016/j.cell.2007.01.029>
15. 2009) Patients at high risk for ovarian cancer should undergo routine screening. Clin. Ovarian Cancer 5, 83-89.
< , B. Y. (https://doi.org/10.3816/COC.2009.n.015>
16. 2006) RASmediated epigenetic inactivation of OPCML in oncogenic transformation of human ovarian surface epithelial cells. FASEB J. 20, 497-499.
< , F. C., Young, T. W., Liu, J., Cheng, X. (https://doi.org/10.1096/fj.05-4586fje>
17. 2004) Wnt inhibitory factor-1 is silenced by promoter hypermethylation in human lung cancer. Cancer Res. 64, 4717-4720.
< , J., He, B., You, L., Xu, Z., Lee, A. Y., Mikami, I., Reguart, N., Rosell, R., McCormick, F., Jablons, D. M. (https://doi.org/10.1158/0008-5472.CAN-04-1389>
18. 2011) Frequent promoter hypermethylation of BRCA2, CDH13, MSH6, PAX5, PAX6 and WT1 in ductal carcinoma in situ and invasive breast cancer. J. Pathol. 225, 222-231.
< , C. B., Verschuur-Maes, A. H., van Diest, P. J. (https://doi.org/10.1002/path.2930>
19. 2012) Prognostic and diagnostic significance of DNA methylation patterns in high grade serous ovarian cancer. Gynecol. Oncol. 124, 582-588.
< , C., Gloss, B. S., Warton, K., Barton, C. A., Statham, A. L., Scurry, J. P., Tabor, B., Nguyen, T. V., Qu, W., Samimi, G., Hacker, N. F., Sutherland, R. L., Clark, S. J., O’Brien, P. M. (https://doi.org/10.1016/j.ygyno.2011.11.026>
20. 2005) Methylation-specific MLPA (MS-MLPA): simultaneous detection of CpG methylation and copy number changes of up to 40 sequences. Nucleic Acids Res. 33, e128.
< , A. O., Ameziane, N., Duarte, H. M., Vijzelaar, R. N., Waisfisz, Q., Hess, C. J., Schouten, J. P., Errami, A. (https://doi.org/10.1093/nar/gni127>
21. 2011) Altered methylation at microRNA-associated CpG islands in hereditary and sporadic carcinomas: a methylation-specific multiplex ligation-dependent probe amplification (MSMLPA)-based approach. Mol. Med. 17, 726-735.
< , W., Perkiö, E., Kaur, S., Peltomäki, P. (https://doi.org/10.2119/molmed.2010.00239>
22. 2005) Frequent epigenetic inactivation of Wnt inhibitory factor-1 in human gastrointestinal cancers. Oncogene 24, 7946-7952.
< , H., Yamamoto, H., Hirata, T., Miyamoto, N., Oki, M., Nosho, K., Adachi, Y., Endo, T., Imai, K., Shinomura, Y. (https://doi.org/10.1038/sj.onc.1208910>
23. 2011) Tyrosine kinase A receptor (trkA): a potential marker in epithelial ovarian cancer. Gynecol. Oncol. 121, 13-23.
< , V., Gabler, F., Muñoz, M., Yazigi, R., Paredes, A., Selman, A., Vega, M., Romero, C. (https://doi.org/10.1016/j.ygyno.2010.12.341>
24. Tavassoli, F. A, Devilee, P. (Eds.) (2003) World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. IARC Press, Lyon, 113-202.
25. 2006) Involvement of GATA-4/-5 transcription factors in ovarian carcinogenesis. Cancer Lett. 241, 281-288.
< , K., Akiyama, Y., Aso, T., Yuasa, Y. (https://doi.org/10.1016/j.canlet.2005.10.039>
26. 2010) Methylation of GATA-4 and GATA-5 and development of sporadic gastric carcinomas. World J. Gastroenterol. 16, 1201-1208.
< , X. Z., Akiyama, Y., Pan, K. F., Liu, Z. J., Lu, Z. M., Zhou, J., Gu, L. K., Dong, C. X., Zhu, B. D., Ji, J. F., You, W. C., Deng, D. J. (https://doi.org/10.3748/wjg.v16.i10.1201>
27. 2001) Hypermethylation of the CpG island of the RASSF1A gene in ovarian and renal cell carcinomas. Int. J. Cancer 94, 212-217.
< , J. H., Dammann, R., Pfeifer, G. P. (https://doi.org/10.1002/ijc.1466>
28. 2012) The dynamics and prognostic potential of DNA methylation changes at stem cell gene loci in women’s cancer. PLoS Genet. 8, e1002517.
< , J., Jones, A., Lee, S. H., Ng, E., Fiegl, H., Zikan, M., Cibula, D., Sargent, A., Salvesen, H. B., Jacobs, I. J., Kitchener, H. C., Teschendorff, A. E., Widschwendter, M. (https://doi.org/10.1371/journal.pgen.1002517>